The SNS indicated that those centers are being erected all over the country, as part of a comprehensive official strategy to deal with thee growing needs of diabetics’ patients.

According information released at a scientific forum in September in Cuba, the North American and Caribbean regions perform some 258,000 amputations every year, while the figure is 10,000 are estimated in 12 months, due to diabetic foot ulcers.

These data were published by experts Juan Vicente Mendez, Head of the Department of Vascular, Endovascular and Diabetic Foot Surgery at the Francisco Moscoso Puello Hospital, and Rafiel Vasquez Checo, coordinator of the Department of Ambulatory Cure and Diabetic Foot Unit at the Jose Maria Cabral y Baez Regional Hospital.

Both joined doctors from other countries in an international Congress in Havana, where the results of the “Recombinant Human Epidermal Growth Factor” treatment, which is applied in the integral attention units for this type of lesion, were presented, according to local media on Wednesday.

On that occasion, Heberprot-P was presented as a novel Cuban drug prescribed for the therapy of diabetic foot ulcers, based on recombinant human growth factor, by means of intralesional infiltration directly into the wound.

The SNS specified that the new healthcare units will be located in the following hospitals: Doctor Jaime Oliver Pino, San Pedro de Macoris; Inmaculada Concepcion, Sanchez Ramirez; Municipal Imbert, Puerto Plata; in the Marcelino Velez Santana, Santo Domingo and Ing. Luis L. Bogaert, in Valverde.

Also hosting this service will be provincial hospitals Nuestra Señora de Regla, Peravia; Doctor Toribio Bencosme, Espaillat; San Bartolome, Bahoruco; Padre Fantino, Montecristi, and San Jose de Ocoa in the town of the same name.

Ied/omr/ro/mpv